Rivoglitazone

From WikiMD.org
Jump to navigation Jump to search

Rivoglitazone

Rivoglitazone (pronounced as ri-vo-gli-ta-zone) is a thiazolidinedione derivative, which is a class of antidiabetic drugs that are used in the management of type 2 diabetes.

Etymology

The term 'Rivoglitazone' is derived from the combination of the words 'Rivo' and 'glitazone'. 'Rivo' is a prefix used in pharmaceutical nomenclature, while 'glitazone' is a suffix used for drugs that belong to the thiazolidinedione class.

Pharmacology

Rivoglitazone works by binding to the peroxisome proliferator-activated receptor gamma (PPARγ), a type of nuclear receptor that is highly expressed in tissues that regulate glucose levels, such as adipose tissue and the liver. By activating PPARγ, Rivoglitazone increases the transcription of insulin-responsive genes, leading to better glucose control.

Related Terms

  • Thiazolidinedione: A class of drugs that Rivoglitazone belongs to. These drugs are used to treat type 2 diabetes by reducing insulin resistance.
  • Peroxisome proliferator-activated receptor gamma (PPARγ): A nuclear receptor that Rivoglitazone binds to in order to exert its antidiabetic effects.
  • Type 2 diabetes: A chronic condition that Rivoglitazone is used to manage. It is characterized by high blood sugar levels due to insulin resistance or a lack of insulin.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski